Credit Suisse analyst Judah Frommer downgrades Pear Therapeutics (NASDAQ:PEAR) from Outperform to Neutral and lowers the price target from $7 to $1.
Credit Suisse Downgrades Pear Therapeutics to Neutral, Lowers Price Target to $1
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.